ATE330967T1 - An her2 bindende peptidverbindungen - Google Patents

An her2 bindende peptidverbindungen

Info

Publication number
ATE330967T1
ATE330967T1 AT00946990T AT00946990T ATE330967T1 AT E330967 T1 ATE330967 T1 AT E330967T1 AT 00946990 T AT00946990 T AT 00946990T AT 00946990 T AT00946990 T AT 00946990T AT E330967 T1 ATE330967 T1 AT E330967T1
Authority
AT
Austria
Prior art keywords
her2
novel compounds
peptide compounds
erbb2
provides
Prior art date
Application number
AT00946990T
Other languages
English (en)
Inventor
Mark S Dennis
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE330967T1 publication Critical patent/ATE330967T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
AT00946990T 1999-07-02 2000-06-30 An her2 bindende peptidverbindungen ATE330967T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14223299P 1999-07-02 1999-07-02

Publications (1)

Publication Number Publication Date
ATE330967T1 true ATE330967T1 (de) 2006-07-15

Family

ID=22499090

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00946990T ATE330967T1 (de) 1999-07-02 2000-06-30 An her2 bindende peptidverbindungen

Country Status (9)

Country Link
US (1) US6987088B2 (de)
EP (1) EP1189931B1 (de)
JP (2) JP4387625B2 (de)
AT (1) ATE330967T1 (de)
AU (1) AU779612C (de)
CA (1) CA2373721C (de)
DE (1) DE60028970T2 (de)
IL (2) IL147271A0 (de)
WO (1) WO2001001748A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660843B1 (en) † 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
WO2003061559A2 (en) * 2001-10-12 2003-07-31 University Of Vermont And State Agricultural College Binding peptides specific for the extracellular domain of erbb2 and uses therefor
JP4491240B2 (ja) 2002-01-17 2010-06-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア Ｉｇｆｂｐ−２およびｉｇｆｂｐ−５を阻害する二重特異性アンチセンスオリゴヌクレオチド、並びにこれらの使用方法
DE10208877B4 (de) * 2002-03-01 2009-04-09 Erdmann, Volker A., Prof.Dr. Verwendung eines Streptavidin- Bindungspeptides
WO2003074546A2 (de) * 2002-03-01 2003-09-12 Erdmann Volker A Streptavidin-bindungspeptid
EP2902491A1 (de) 2003-03-19 2015-08-05 Biogen MA Inc. NOGO Rezeptor bindendes Protein
ATE416190T1 (de) * 2003-07-04 2008-12-15 Affibody Ab Polypeptide mit bindungsaffinität für her2
ATE530196T1 (de) * 2004-03-03 2011-11-15 Iq Therapeutics Bv Menschliches anthrax-toxin neutralisierende monoklonale antikörper und verfahren zu deren anwendung
WO2005113001A1 (en) * 2004-05-20 2005-12-01 Zymogenetics, Inc. Methods of treating cancer using il-21 and monoclonal antibody therapy
EP1776136B1 (de) 2004-06-24 2012-10-03 Biogen Idec MA Inc. Behandlung von entmyelinisierenden erkrankungen
KR20110050567A (ko) * 2004-07-22 2011-05-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
EP1807106A2 (de) * 2004-10-05 2007-07-18 Oregon Health and Science University Zusammensetzungen und verfahren zur behandlung von erkrankungen
KR20130105885A (ko) 2005-01-05 2013-09-26 에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. 상보성 결정부위와 다른 분자의 부위에서 처리된 결합성을 갖는 합성 면역글로불린 영역
AU2006269458B2 (en) 2005-07-08 2012-11-08 Biogen Ma Inc. Sp35 antibodies and uses thereof
JP2009511060A (ja) * 2005-10-14 2009-03-19 バイオレクシス ファーマシューティカル コーポレーション ナトリウム利尿ペプチド修飾されたトランスフェリン融合タンパク質
NZ569428A (en) 2005-12-02 2012-11-30 Biogen Idec Inc Treatment of conditions involving demyelination with a Sp35 antagonist
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
WO2008019290A2 (en) * 2006-08-04 2008-02-14 Astrazeneca Ab Human antibodies to erbb 2
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US20090258005A1 (en) * 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
ES2627223T3 (es) 2007-06-26 2017-07-27 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Presentación de agentes de unión
CA2701189C (en) * 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
JP5754046B2 (ja) * 2007-11-08 2015-07-22 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 脱髄を伴う状態の治療におけるｌｉｎｇｏ−４アンタゴニストの使用
EP2113255A1 (de) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Zytotoxisches Immunglobulin
DK2982695T3 (da) * 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
EP2145901B1 (de) 2008-07-18 2012-11-14 Technische Universität Braunschweig Rekombinante anti-MUC1-Antikörper
US9586996B2 (en) * 2010-04-30 2017-03-07 Esperance Pharmaceuticals, Inc. Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
BR112013023537B1 (pt) * 2011-03-28 2022-05-31 S.I.S. Shulov Innovative Science Ltd Composição tópica para o tratamento de um distúrbio da pele
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
IL312872A (en) 2011-06-28 2024-07-01 Inhibrx Inc Methods for purifying fusion proteins containing serphin
NZ702178A (en) 2012-05-14 2017-01-27 Biogen Ma Inc Lingo-2 antagonists for treatment of conditions involving motor neurons
WO2015138435A1 (en) 2014-03-11 2015-09-17 Molecular Templates, Inc. Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
EP3872090A1 (de) 2014-03-11 2021-09-01 Molecular Templates, Inc. Proteine mit aminoterminalen proximalen shiga-toxin-a-untereinheiteneffektorregionen und gegen zellen gerichteten immunglobulinbindungsregionen
ES2819863T3 (es) 2014-04-11 2021-04-19 Medimmune Llc Anticuerpos contra HER2 biespecíficos
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
JP6771492B2 (ja) 2015-05-30 2020-10-21 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 脱免疫化された志賀毒素ａサブユニット足場及びそれを含む細胞標的化分子
MX2018001208A (es) 2015-07-26 2018-03-26 Molecular Templates Inc Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+.
WO2017200787A1 (en) 2016-05-18 2017-11-23 Arizona Board Of Regents On Behalf Of Arizona State University Peptide-dna chimeras for treatment of her overexpressing cancers
WO2018048755A1 (en) * 2016-09-06 2018-03-15 Academia Sinica ErbB2 REGULATES AUTOPHAGIC FLUX TO MODULATE THE PROTEOSTASIS OF APP-CTFs IN ALZHEIMER'S DISEASE
KR102590672B1 (ko) 2017-01-25 2023-10-18 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
MX2019009726A (es) 2018-04-17 2020-02-05 Molecular Templates Inc Moleculas con direccion hacia her2 que comprenden andamiajes de la sub-unidad a de la toxina shiga desinmunizados.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5578482A (en) * 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
US5279966A (en) * 1992-04-02 1994-01-18 The Trustees Of Columbia University In The City Of New York Cloning, expression and uses of a novel secreted protein, F-spondin
US5871969A (en) * 1996-02-12 1999-02-16 Human Genome Sciences, Inc. Nucleic acids encoding human neuronal attachment factor-1
CA2269204C (en) * 1996-10-18 2012-01-24 Genentech, Inc. Anti-erbb2 antibodies
EP1001981A4 (de) * 1997-06-17 2000-09-27 Human Genome Sciences Inc Heregulin-ähnlicher faktor
AU4469997A (en) * 1997-09-17 1999-04-05 Urs Eppenberger Heregulin-gamma
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
CA2318857C (en) * 1998-02-04 2013-09-24 Genentech, Inc. Use of heregulin as an epithelial cell growth factor
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists

Also Published As

Publication number Publication date
EP1189931B1 (de) 2006-06-21
IL147271A0 (en) 2002-08-14
IL147271A (en) 2014-07-31
JP2010004885A (ja) 2010-01-14
WO2001001748A2 (en) 2001-01-11
AU779612B2 (en) 2005-02-03
US20030171278A1 (en) 2003-09-11
CA2373721C (en) 2013-10-15
EP1189931A2 (de) 2002-03-27
CA2373721A1 (en) 2001-01-11
DE60028970T2 (de) 2007-02-15
JP4387625B2 (ja) 2009-12-16
DE60028970D1 (de) 2006-08-03
US6987088B2 (en) 2006-01-17
JP2003503075A (ja) 2003-01-28
AU779612C (en) 2005-12-15
WO2001001748A3 (en) 2001-07-26
AU6066900A (en) 2001-01-22

Similar Documents

Publication Publication Date Title
ATE330967T1 (de) An her2 bindende peptidverbindungen
AU2002305450A1 (en) Proteomimetic compounds and methods
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
GB0222495D0 (en) Compounds
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
AU3368497A (en) Human dnase i hyperactive variants
IL173348A (en) Thienopyridine compounds, pharmaceuticals containing them and their use in the preparation of drugs
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
ATE514718T1 (de) Peptabody für krebsbehandlung
WO2004076614A3 (de) Humane nukleinsäuresequenzen aus prostatakarzinomen
AU1454502A (en) Ige receptor antagonists
WO2003102185A3 (en) Methods and compositions for treating neoplasia relating to hnrnp a1 and a2 nucleic acid molecules
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
IL207012A (en) 28sgp medicinal product and 28sgp accent cancer treatment vaccine
EA200600995A1 (ru) Молекулы, ингибирующие ангиогенез, и их применение в лечении и диагностике рака
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004031354A3 (en) Human sarcoma-associated antigens
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
WO2003080624A3 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
WO2004004649A3 (en) Compositions and methods for the treatment of immune related diseases
WO2001066740A3 (en) Compositions and methods for the treatment of immune related diseases

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties